Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 17/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30328300 | 1.00 | HCRTR2 (0.41) | HCRTR2HCRTR1EIF2AK4CYP1A2CYP3A4 | |
| SCHEMBL25163834 | 0.91 | HCRTR2 (0.43) | HCRTR2HCRTR1 | |
| SCHEMBL30327812 | 0.91 | HCRTR2 (0.43) | HCRTR2HCRTR1 | |
| SCHEMBL30328520 | 0.88 | HCRTR2 (0.41) | HCRTR2HCRTR1 | |
| SCHEMBL25164376 | 0.88 | HCRTR2 (0.41) | HCRTR2HCRTR1 | |
| SCHEMBL25164369 | 0.85 | CYP3A4 (0.36) | HCRTR2HCRTR1EIF2AK4CYP1A2CYP3A4 | |
| SCHEMBL30328371 | 0.85 | CYP3A4 (0.36) | HCRTR2HCRTR1EIF2AK4CYP1A2CYP3A4 | |
| SCHEMBL25164424 | 0.85 | HCRTR2 (0.38) | HCRTR2HCRTR1 | |
| SCHEMBL30327873 | 0.85 | HCRTR2 (0.38) | HCRTR2HCRTR1 | |
| SCHEMBL25163861 | 0.85 | HCRTR2 (0.40) | HCRTR2HCRTR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | HCRTR2 2687/4885HCRTR1 2849/4885EIF2AK4 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.